Here's What's Coming From Amfil Technologies Inc (OTCMKTS:AMFE)

Amfil Technologies Inc (OTCMKTS:AMFE) is a company we first highlighted as being one to watch back in mid February. At the time, the company had just logged a short term run, and was trading in and around the $0.018 mark. The run grabbed our attention, and we took a closer look at Amfil from an operational perspective in an attempt to figure out whether the run was a flash in the pan, or whether there might be some longer term potential in the stock.We came down in favor of the latter.Specifically, we concluded that a flurry of operational catalysts set to hit press throughout the remainder of 2017 (post February) should set off some upside momentum if and when they dropped.As it turned out, that's exactly what happened.At last close (Thursday, before markets broke for Easter), Amfil traded for $0.05 a share. That's a more than 175% run since our highlighting of the company to our readers, and 525% premium to Amfil's 2017 open price.Again, then, it's time to ask the question – what's next? And again, it looks as though our answer is going to fall favorably on the company. Not only that, but we're going with exactly the same thesis – that a host of near term catalysts should spark some upside momentum, and that this momentum should carry through as the second quarter matures into the third.So what are we looking at?We're not the kind of traders that use Twitter to inform our market decisions. However, in this instance, we're going to go against our better judgment and reference Amfil's Twitter account for the catalysts we're watching.By way of a quick introduction to the company, and before we look at the specific catalysts, Amfil is an umbrella entity that operates branded subsidiaries. Its three lead brands right now are Interloc-Kings Inc, a Toronto hardscape construction company; GroZone, a medical marijuana chemical sanitization entity; and Snakes & Lagers and Snakes & Lattes, which are the operators of board game themed bars and cafes, also in Toronto.So, first up there's an uplisting to OTC as a fully reporting company. This has held back Amfil for a while, and when it happens, it's going to increase visibility. There's no set data for this, but we expect it during the second quarter.

https://t.co/NQd1QkeU54 (OTC MARKETS) reached out to us today to assist with streamlining the up-listing process to ensure everything proceeds as planned

— Amfil Technologies (@AmfilTech) April 4, 2017

Next, and more near term, we're looking at an announcement regarding the GROZone operation, and a deal with an as yet unnamed public company to market and distribute its antimicrobial technology. In February, management noted this announcement should hit press in the coming weeks. At the end of March, this changed to coming days. Last week, Amfil published this on its Twitter account:

We intended to release details of the new GROzone deal with the hydroponic developer tomorrow but their IR department has requested time

— Amfil Technologies (@AmfilTech) April 6, 2017

As the deal is with a public company (not OTC) they requested time to prepare a joint release for their shareholders concurrent with Amfil's

— Amfil Technologies (@AmfilTech) April 6, 2017

This deal is a monumental step for the GROzone #EcoPro3 product line. We are excited to release the details to shareholders shortly!

— Amfil Technologies (@AmfilTech) April 6, 2017

And most recently:

We know shareholders are patiently awaiting the Grozone update, the news will be released next week! Happy Easter from Amfil Technologies!

— Amfil Technologies (@AmfilTech) April 13, 2017

So this suggests we should see some news this week regarding the deal. Markets are primed for this news, and we expect that much of the run we've seen in the last couple of weeks is in anticipation of it being a real driver for Amfil. If it comes out in line with these expectations, then, Amfil should breakout.That's not all.There's a pending update on a deal between the above mentioned Snakes and Lattes brand and Cineplex, which is rumored to involve between ten and fifteen new locations, or a joint venture between the two companies. We've been watching this deal closely to see how it's progressing, and management put out this news a few days ago on Twitter:

The Snakes & Lattes team will sit down with Cineplex management next Wednesday

— Amfil Technologies (@AmfilTech) April 12, 2017

Followed by:

Snakes and Lattes is making moves, stay posted for an update before months end.

— Amfil Technologies (@AmfilTech) April 11, 2017

So that suggests we're going to get a preliminary terms agreement this week, and that then we should the company put out an official (i.e. not on Twitter!) release concerning the terms before the end of April.There's also the potential for earnings to hit press this month (although this may push into May) and the finalizing of an exchange of 20 million outstanding to preferred. Again, this may hit press this month, but chances are it will happen in conjunction with the just mentioned report release.As we said last time, this is far from a risk free play. Dilution is almost inevitable, and shareholders that pick up a position now in anticipation of any near term run are going to have to shoulder this dilution (and by proxy, factor it in as a risk ahead of any exposure). Again, however, as we said last time, the potential for run room largely mitigates any dilutive impact of an issue and raise, and we remain aggregate bullish on Amfil near to medium term.We will be updating our subscribers as soon as we know more. For the latest updates on AMFE, sign up below!Disclosure: We have no position in AMFE and have not been compensated for this article.